revealed that another common chemotherapy drug for bladder cancer—gemcitabine—can improve infiltration quantity of CD8+T cells and impair immunosuppressive immune cells in TME.[41] In our preclinical animal experiment, cotreatment of BCAT2 loss and anti‐PD‐1 mab displayed a more distinct antitumor efficacy compared to monotherapy of anti‐PD‐1 mab in immune‐competent mice, which provides an innovative treatment strategy for ICB‐resistance patients. Here, CD8A is linked to urinary bladder cancer.